NASDAQ:NVCRNovocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVCR stock has decreased by 10.8% and is now trading at $60.07. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Novocure.

Novocure will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The medical equipment provider earned $101.83 million during the quarter, compared to the consensus estimate of $102.10 million. Novocure had a return on equity of 4.39% and a net margin of 2.34%. The business's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.13) earnings per share. View Novocure's earnings history.

8 brokers have issued 1 year target prices for Novocure's stock. Their forecasts range from $58.00 to $90.00. On average, they expect Novocure's stock price to reach $79.00 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price. View analysts' price targets for Novocure.

Media coverage about NVCR stock has trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Novocure.

Novocure saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,070,000 shares, an increase of 9.1% from the June 15th total of 3,730,000 shares. Based on an average daily trading volume, of 885,100 shares, the short-interest ratio is presently 4.6 days. Currently, 4.9% of the shares of the company are sold short. View Novocure's Current Options Chain.

Some companies that are related to Novocure include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Tandem Diabetes Care (TNDM), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA) and Merit Medical Systems (MMSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), NVIDIA (NVDA), Washington Prime Group (WPG) and Roper Technologies (ROP).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.02%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View institutional ownership trends for Novocure.

NVCR stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $60.07.

Novocure has a market capitalization of $6.03 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]